Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Lotte Marieke Knapen, Rutger H. T. Koornstra, Johanna H. M. Driessen, Bas Van Vlijmen, Sander Croes, Stein J. Schalkwijk, Angela Colbers, Winald Gerritsen, David Burger, Frank de Vries, Nielka P. Van Erp

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this